210 related articles for article (PubMed ID: 35660330)
1. Evaluation of prime and prime-boost immunization strategies in BALB/c mice inoculated with Leishmania infantum transfected with toxic plasmids.
Augusto Sanches Roque G; Esteves Zorgi N; Janaína Soares Rocha F; Flóro E Silva M; Fernanda Araújo T; Ruiz Abánades D; Giorgio S
Vaccine; 2022 Jul; 40(31):4105-4115. PubMed ID: 35660330
[TBL] [Abstract][Full Text] [Related]
2. Leishmania infantum transfected with toxic plasmid induces protection in mice infected with wild type L. infantum or L. amazonensis.
Zorgi NE; Arruda LV; Paladine I; Roque GAS; Araújo TF; Brocchi M; Barral M; Sanchiz Á; Requena JM; Abánades DR; Giorgio S
Mol Immunol; 2020 Nov; 127():95-106. PubMed ID: 32949849
[TBL] [Abstract][Full Text] [Related]
3. Antigenicity of
Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
Front Immunol; 2018; 9():843. PubMed ID: 29740446
[No Abstract] [Full Text] [Related]
4. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice.
Iborra S; Soto M; Carrión J; Nieto A; Fernández E; Alonso C; Requena JM
Infect Immun; 2003 Nov; 71(11):6562-72. PubMed ID: 14573678
[TBL] [Abstract][Full Text] [Related]
5. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.
Martins VT; Duarte MC; Chávez-Fumagalli MA; Menezes-Souza D; Coelho CS; de Magalhães-Soares DF; Fernandes AP; Soto M; Tavares CA; Coelho EA
Parasit Vectors; 2015 Jul; 8():363. PubMed ID: 26160291
[TBL] [Abstract][Full Text] [Related]
6. Immunization of Experimental Dogs With Salivary Proteins From
Abbehusen MMC; Cunha J; Suarez MS; Teixeira C; Almeida VDA; Pereira LDS; Bordoni M; Gil-Santana L; Solcà MDS; Fraga DBM; Fischer L; Bozza PT; Veras PST; Valenzuela JG; Kamhawi S; Andrade BB; Brodskyn CI
Front Immunol; 2018; 9():2558. PubMed ID: 30519235
[TBL] [Abstract][Full Text] [Related]
7. Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis.
Martins VT; Chávez-Fumagalli MA; Lage DP; Duarte MC; Garde E; Costa LE; da Silva VG; Oliveira JS; Magalhães-Soares DF; Teixeira SM; Fernandes AP; Soto M; Tavares CA; Coelho EA
PLoS One; 2015; 10(9):e0137683. PubMed ID: 26367128
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters.
Pereira L; Abbehusen M; Teixeira C; Cunha J; Nascimento IP; Fukutani K; dos-Santos W; Barral A; de Oliveira CI; Barral-Netto M; Soto M; Brodskyn CI
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003490. PubMed ID: 25642946
[TBL] [Abstract][Full Text] [Related]
9. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.
Saljoughian N; Taheri T; Zahedifard F; Taslimi Y; Doustdari F; Bolhassani A; Doroud D; Azizi H; Heidari K; Vasei M; Namvar Asl N; Papadopoulou B; Rafati S
PLoS Negl Trop Dis; 2013; 7(4):e2174. PubMed ID: 23638195
[TBL] [Abstract][Full Text] [Related]
10. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
[TBL] [Abstract][Full Text] [Related]
11. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T
Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586
[TBL] [Abstract][Full Text] [Related]
12. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK.
Ramiro MJ; Zárate JJ; Hanke T; Rodriguez D; Rodriguez JR; Esteban M; Lucientes J; Castillo JA; Larraga V
Vaccine; 2003 Jun; 21(19-20):2474-84. PubMed ID: 12744881
[TBL] [Abstract][Full Text] [Related]
13. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis.
Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J
Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113
[TBL] [Abstract][Full Text] [Related]
14. Immune response in susceptible BALB/c mice immunized with DNA encoding Lipophosphoglycan 3 of Leishmania infantum.
Pirdel L; Hosseini AZ; Rasouli M
Parasite Immunol; 2014 Dec; 36(12):700-7. PubMed ID: 25244583
[TBL] [Abstract][Full Text] [Related]
15. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
Front Immunol; 2018; 9():465. PubMed ID: 29599776
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus enhances the protection achieved by a DNA vaccine against Leishmania infantum.
Martínez-Flórez A; Martori C; Monteagudo PL; Rodriguez F; Alberola J; Rodríguez-Cortés A
Parasit Vectors; 2020 Jun; 13(1):294. PubMed ID: 32517744
[TBL] [Abstract][Full Text] [Related]
17. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
Rafati S; Zahedifard F; Nazgouee F
Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969
[TBL] [Abstract][Full Text] [Related]
18. A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis.
Lopes Valentim Di Paschoale Ostolin T; Rodrigues Gusmão M; Augusto Siqueira Mathias F; Mirelle de Oliveira Cardoso J; Mendes Roatt B; Dian de Oliveira Aguiar-Soares R; Conceição Ruiz J; de Melo Resende D; Cristiane Fortes de Brito R; Barbosa Reis A
Cell Immunol; 2022 Oct; 380():104592. PubMed ID: 36084402
[TBL] [Abstract][Full Text] [Related]
19. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
20. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
